<DOC>
	<DOC>NCT00065728</DOC>
	<brief_summary>The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.</brief_summary>
	<brief_title>Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<criteria>Patients with subfoveal exudative agerelated macular degeneration (AMD) who were previously enrolled in longterm studies with anecortave acetate. Other protocoldefined inclusion criteria may apply. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>AMD</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>Anecortave</keyword>
	<keyword>Acetate</keyword>
	<keyword>Wet form of age-related macular degeneration</keyword>
	<keyword>CNV</keyword>
	<keyword>Anecortave Acetate</keyword>
</DOC>